Age-related macular degeneration (AMD, neovascular/wet)
- Intravitreal anti-VEGF is first-line
- Aflibercept/ranibizumab/bevacizumab are key agents
- Faricimab adds VEGF/Ang-2 pathway blockade
- Repeat injections are guided by OCT/activity
- Treat promptly to preserve central vision
- Smoking cessation + fellow-eye monitoring matter
Use at a glance
- Intravitreal anti-VEGF is first-line
Monitoring / follow-up
- Faricimab adds VEGF/Ang-2 pathway blockade
- Repeat injections are guided by OCT/activity
Practical pearls
- Aflibercept/ranibizumab/bevacizumab are key agents
Response / follow-up
- Treat promptly to preserve central vision
- Smoking cessation + fellow-eye monitoring matter
Self-check
- What is first-line treatment for neovascular/wet AMD?
Intravitreal anti-VEGF therapy.
Drugs used for this (4)
All clinical uses · Open the interactive console ↗
